Analysts Set Satellos Bioscience Inc. (NASDAQ:MSLE) PT at $19.75

Satellos Bioscience Inc. (NASDAQ:MSLE) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $19.75.

Several research analysts recently weighed in on MSLE shares. Guggenheim began coverage on shares of Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price objective on the stock. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Wells Fargo & Company set a $18.00 price target on shares of Satellos Bioscience in a report on Thursday, July 9th. Finally, Leerink Partners initiated coverage on shares of Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 price objective for the company.

Satellos Bioscience Stock Up 2.2%

Shares of Satellos Bioscience stock opened at $8.95 on Wednesday. The firm has a market capitalization of $186.52 million, a PE ratio of -5.59 and a beta of 1.53. Satellos Bioscience has a 52 week low of $4.64 and a 52 week high of $13.39. The firm has a 50 day moving average price of $7.11.

Satellos Bioscience (NASDAQ:MSLE) last issued its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, analysts expect that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.